N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL Basic information
- Product Name:
- N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL
- Synonyms:
-
- 6-o-stearoyl-n-acetylmuramyl-alanylisoglutamine
- N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL
- N-acetylmuramyl-6-O-stearoyl-L-alanyl-*D-isogluta
- N-ACETYLMURAMYL-6-O-STEAROYL-L-ALANYL-D-ISOGLUTAMINE)
- Ac-(6-O-stearoyl)-MuraMyl-Ala-D-Isogln-OH, L18-MDP
- Ac-(6-O-stearoyl)-muramyl-Ala-D-Glu-NH
- D-α-Glutamine, N-[N-acetyl-6-O-(1-oxooctadecyl)muramoyl]-L-alanyl-
- CAS:
- 60398-08-5
- MF:
- C37H66N4O12
- MW:
- 758.94
- Mol File:
- 60398-08-5.mol
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL Chemical Properties
- storage temp.
- −20°C
- Sequence
- Ac-(6-O-stearoyl)-muramyl-Ala-{d-Glu}-NH2
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL Usage And Synthesis
Uses
L18-MDP is a derivative of muramyl dipeptide, an antibacterial agent. L18-MDP has antibacterial activity and has potential applications in bacterial and fungal infections[1].
in vivo
L18-MDP (100 μg; s.c.; single dose) has anti-infection effect in mice infected with Escherichia coli or Klebsiella pneumoniae[1].
L18-MDP (100 μg or 1000 μg; s.c., i.p., i.v. or p.o.; single dose) increases the survival rate of mice infected with Escherichia coli and improves the pathological tissue of mice infected with Listeria monocytogenes[1].
L18-MDP (100 μg or 200 μg; s.c. or i.p.; once daily for 3 days) increases the survival rate of mice infected with Candida albicans[1].
| Animal Model: | Mice infected with Escherichia coli, Klebsiella pneumoniae or Listeria monocytogenes[1]. |
| Dosage: | 100 μg or 1000 μg. |
| Administration: | Subcutaneous injection, intraperitoneal injection, intravenous injection or oral gavage; single dose. |
| Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
| Animal Model: | Mice infected with Candida albicans[1]. |
| Dosage: | 100 μg or 200 μg. |
| Administration: | Subcutaneous injection or intraperitoneal injection; once daily for 3 days. |
| Result: | Strengthened the phagocytosis of the microorganisms, weakened the virus activity, increased the survival rate and improved the pathological tissue. |
References
[1] Osada Y, et al. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun. 1982 Jul;37(1):292-300. DOI:10.1128/iai.37.1.292-300.1982
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYLSupplier
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 17705183659
- sales@njleonbiotech.com
- Tel
- 0571-87213919
- Eric@peptidego.com
- Tel
- 18115476705
- sales@tgpeptide.com
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL(60398-08-5)Related Product Information
- 1-ALPHA-O-BENZYL-N-ACETYLMURAMYL-ALA-D-ISOGLN-LYS(TRANS(M-NITROCINNAMOYL)-NH2)-NH2
- Romurtide
- Temurtide
- N-ACETYLMURAMYL-D-ALANYL-D-ISOGLUTAMINE)
- AC-MURAMYL-ALA-GLU-NH2
- Muramyl Dipeptide
- 2-ACETAMIDO-2-DEOXY-3-O-METHYL-D-GLUCOPYRANOSE
- H-ALA-D-GLU-NH2
- N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine
- N-ACETYL-ALPHA-D-GLUCOSAMINE
- 2(2-HYDROXYETHOXY)ACETAMIDE
- D-GLUTAMIC ACID ALPHA-AMIDE HYDROCHLORIDE
- N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE-6-O-STEAROYL